[A new method for the comparative quantitative assessment of a radiomodifying effect]

Area of Science:

• Radiation Biology
• Pharmacology
• Toxicology

Background:

• Assessing the efficacy of radioprotective agents is crucial for mitigating radiation damage.
• Existing methods, like the dose reduction factor (DRF), have limitations in comprehensively evaluating radioprotector efficiency.
• A need exists for a more robust and biologically relevant metric to quantify radioprotective effects.

Purpose of the Study:

• To introduce a new criterion for the quantitative estimation of radioprotective effect, termed radioprotector efficiency.
• To describe the methodology for assessing this integral index of protection.
• To compare the advantages of the new criterion over the traditional dose reduction factor (DRF).

Main Methods:

• The proposed criterion is an integral index based on the proportion of surviving animals in experimental and control groups across a studied dose range.
• Methods for assessing this criterion and its comparative advantages over DRF are detailed.
• The efficiency of several radioprotective agents (Cystamine, Naphthysin, Indralin, Thymogen, Lymphokinin, Prodigiosan, and Polyribonate) was evaluated.

Main Results:

• A new integral index for quantifying radioprotector efficiency has been successfully developed and applied.
• The criterion provides a biologically relevant estimation based on survival rates.
• The study demonstrates the application of this new criterion to evaluate multiple known radioprotective compounds.

Conclusions:

• The suggested integral index offers a novel and potentially more accurate method for estimating radioprotector efficiency.
• This new criterion provides a valuable alternative to the conventional dose reduction factor (DRF).
• The proposed method facilitates a more comprehensive comparative estimation of radioprotective effects.